ProCE Banner Activity

CE / CME

The Pivotal Role of the Primary Care Clinician in Managing Patients With Cardiorenal Metabolic Diseases

Multimedia

On-demand recording of expert faculty discussions and case presentations on the critical role of primary care clinicians in managing patients with cardiorenal metabolic diseases, including cardiovascular disease, chronic kidney disease, and diabetes.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: November 29, 2023

Expiration: November 28, 2024

Share

Faculty

Nayan Arora

Nayan Arora, MD

Assistant Clinical Professor
Division of Nephrology
Clinical Lead of the Diabetic Kidney Clinic and inpatient cardiorenal service
University of Washington
Seattle, Washington

Ty Gluckman

Ty Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director, Center for Cardiovascular Analytics, Research and Data Science (CARDS) Providence Heart Institute
Providence St. Joseph Health
Portland, Oregon

Kim Pfotenhauer

Kim Pfotenhauer, DO, FACOFP

Assistant Dean of Clerkship Education
Assistant Professor of Family Medicine
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan

Jay H. Shubrook

Jay H. Shubrook, DO, FACOFP, FAAFP

Professor
Department of Clinical Sciences and Community Health
Diabetologist
Touro University California
College of Osteopathic Medicine
Vallejo, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals

Eli Lilly and Company

Target Audience

This program is intended for primary care physicians, PAs, NPs, and other HCPs who manage patients with cardiorenal metabolic comorbidities.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with cardiorenal metabolic diseases.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the effects of SGLT2 inhibitors beyond glycemic management for patients with cardiorenal metabolic comorbidities

  • Integrate different SGLT2 inhibitors into the treatment for patients with diabetes, HF, and CKD based on clinical evidence and guideline recommendations

  • Implement strategies to collaboratively mitigate adverse effects and optimize access for patients with indications for SGLT2 inhibitors

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Nayan Arora, MD

Assistant Clinical Professor
Division of Nephrology
Clinical Lead of the Diabetic Kidney Clinic and inpatient cardiorenal service
University of Washington
Seattle, Washington

Nayan Arora, MD: consultant/advisor/speaker: AstraZeneca, Bayer.

Ty Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director, Center for Cardiovascular Analytics, Research and Data Science (CARDS) Providence Heart Institute
Providence St. Joseph Health
Portland, Oregon

Ty Gluckman, MD, MHA, FACC, FAHA, FASPC, has no relevant financial relationships to disclose.

Kim Pfotenhauer, DO, FACOFP

Assistant Dean of Clerkship Education
Assistant Professor of Family Medicine
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan

Kim Pfotenhauer, DO, FACOFP: consultant/advisor/speaker: Abbot, Novo Nordisk.

Jay H. Shubrook, DO, FACOFP, FAAFP

Professor
Department of Clinical Sciences and Community Health
Diabetologist
Touro University California
College of Osteopathic Medicine
Vallejo, California

Jay H. Shubrook, DO, FACOFP, FAAFP: consultant/advisor/speaker: Abbott, AstraZeneca, Bayer, Lilly, Nevro, Novo Nordisk.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 29, 2023, through November 28, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Physician Associate Continuing Medical Education
Joint AccreditationClinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until November 28, 2024. PAs should only claim credit commensurate with the extent of their participation.

 

American Board of Internal Medicine Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).